A Study of [14C]-LY3023703 in Healthy Participants

Recruitment & Eligibility

Status: TERMINATED

Sex: Male

Target Recruitment: 18

Inclusion Criteria

Participants will either be sterile or, if sexually active, agree to use approved methods of contraception from the day before dosing until 3 months after the follow-up assessment
Participants will refrain from sperm donation from the day before dosing until 3 months after the follow-up assessment
Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/m^2)
Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
Have given written informed consent approved by Lilly and the IRB governing the site

Exclusion Criteria

Are currently enrolled in, have participated, within the last 30 days, in a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Are participants who have previously completed or withdrawn from this study or any other study investigating LY3023703, and have previously received the investigational product
Have known allergies to LY3023703, related compounds or any components of the formulation, or history of significant atopy
Have recent or ongoing gastrointestinal (GI) symptoms or illnesses, have a history of GI bleeding or perforation, related to previous nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase (COX)2 inhibitor therapy or have active or history of recurrent peptic ulcer/hemorrhage (2 or more distinct episodes of proven ulceration or bleeding)
Have a history of intolerance to NSAIDs or aspirin
Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
Show evidence of alanine aminotransferase or aspartate aminotransferase levels above the normal ranges, confirmed on repeat, or a history of elevated and abnormal liver tests
Have intended use of over-the-counter medications or prescription medication within 14 days prior to dosing. Also within 30 days prior to dosing, any drugs and dietary items that are known inducers or inhibitors of cytochrome P450 (CYP) 3A or CYP2J2 or other drugs that may affect the disposition of LY3023703 or increase risk for complications from the study
Have consumed herbal supplements within 14 days prior to admission or grapefruit juice, grapefruits, grapefruit-containing products, Seville orange juice, Seville oranges, star fruit, or star fruit juice within 7 days prior to dosing or intend to consume during the study
Have donated blood of more than 500 milliliter (mL) within the last month
Have participated in a [14C]-study within the last 6 months prior to admission for this study
Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
A positive alcohol breathalyzer test
A positive cotinine test
Are unwilling to refrain from consuming xanthine-containing food and drink from 48 hours prior to admission until discharge from the Clinical Research Unit (CRU)
Have a defecation pattern less than once per 2 days or acute constipation within 3 weeks of the day before dosing
In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
[^14C]-LY3023703	[^14C]-LY3023703	Single oral dose of 15 mg LY3023703, containing approximately 100 µCi \[\^14C\] labeled drug, administered as an oral solution.

Primary Outcome Measures

Name	Time	Method
Fecal Excretion of LY3023703 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Predose up to 168 hours post dose
Urinary Excretion of LY3023703 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Predose up to 168 hours post dose

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics of LY3023703 and Radioactivity Time of Maximum Observed Concentration (Tmax)	Predose up to 168 hours post dose
Pharmacokinetics of LY3023703 and Radioactivity Maximum Observed Concentration (Cmax)	Predose up to 168 hours post dose
Pharmacokinetics of LY3023703 and Radioactivity Area Under The Concentration-Time Curve From Time Zero to the Last Timepoint With a Measurable Concentration [AUC (0 to Tlast)]	Predose up to 168 hours post dose
Relative Abundance of LY3023703 and the Metabolites of LY3023703 in Urine and Feces	Predose up to 168 hours post dose
Relative Abundance of LY3023703 and the Metabolites of LY3023703 in Plasma	One hour post-dose up to 72 hours post dose

A Study of [14C]-LY3023703 in Healthy Participants

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts